Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

Dean J. Kereiakes, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40% to 50% residual aggregation in response to 20-μmol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalJACC: Cardiovascular Interventions
Volume1
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Percutaneous Coronary Intervention
clopidogrel
Blood Platelets
Aspirin
Antithrombins
Therapeutics
Adenosine Diphosphate
Myocardial Infarction
Safety
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. / Kereiakes, Dean J.; Gurbel, Paul A.

In: JACC: Cardiovascular Interventions, Vol. 1, No. 2, 04.2008, p. 111-121.

Research output: Contribution to journalArticle

@article{d7b5853f93264317bc7826cc9b86cb27,
title = "Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention",
abstract = "Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40{\%} to 50{\%} residual aggregation in response to 20-μmol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.",
author = "Kereiakes, {Dean J.} and Gurbel, {Paul A.}",
year = "2008",
month = "4",
doi = "10.1016/j.jcin.2008.01.005",
language = "English (US)",
volume = "1",
pages = "111--121",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

AU - Kereiakes, Dean J.

AU - Gurbel, Paul A.

PY - 2008/4

Y1 - 2008/4

N2 - Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40% to 50% residual aggregation in response to 20-μmol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.

AB - Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40% to 50% residual aggregation in response to 20-μmol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.

UR - http://www.scopus.com/inward/record.url?scp=41949099615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949099615&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2008.01.005

DO - 10.1016/j.jcin.2008.01.005

M3 - Article

C2 - 19463287

AN - SCOPUS:41949099615

VL - 1

SP - 111

EP - 121

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 2

ER -